Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
6 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is an early-stage preclinical study demonstrating proof-of-concept for a novel theranostic nanoparticle in mouse models of TNBC, with no human data, no clinical outcomes, and no comparison to standard surgical or immunotherapeutic approaches.
Small single-center matched cohort study (31 per group) with retrospective design and surrogate endpoints; findings on concurrent nephropathy and renal function decline are clinically relevant but require validation in larger prospective studies.
This is a single-centre retrospective descriptive study reporting epidemiological frequencies and patterns without a control group, comparison arm, or hypothesis testing; it characterizes disease occurrence but does not establish causation, prognosis, or intervention efficacy.
A novel methodological proposal with algorithmic validation on semi-synthetic and industrial observational data, but without peer review, no confirmatory RCT of the full method, and results presented as descriptive frontier consistency rather than independent statistical significance.
Mechanistic study in animal models of a proposed metabolic axis in lung cancer bone metastasis; no clinical outcome data, human efficacy trials, or direct comparison to standard therapy reported.
This is a narrative review article synthesizing engineering strategies for bacterial therapeutics without presenting original empirical data or meta-analyzed outcomes.